3.4.24.B4: matrix metalloproteinase-13
This is an abbreviated version!
For detailed information about matrix metalloproteinase-13, go to the full flat file.
Word Map on EC 3.4.24.B4
-
3.4.24.B4
-
cartilage
-
chondrocytes
-
osteoarthritis
-
metalloproteinases
-
joint
-
articular
-
aggrecan
-
degeneration
-
mmp-2
-
tnf
-
knee
-
timp-1
-
arthritis
-
synovial
-
interleukin-1
-
proteoglycans
-
degener
-
cox-2
-
osteoblast
-
adamts-5
-
ligament
-
intra-articular
-
collagenases
-
col2a1
-
thrombospondin
-
pulposus
-
runx2
-
cruciate
-
zymography
-
chondrogenic
-
gelatinase
-
meniscus
-
intervertebral
-
subchondral
-
disintegrin
-
endochondral
-
safranin
-
synoviocytes
-
collagenolytic
-
matrix-degrading
-
chondroprotective
-
ossification
-
temporomandibular
-
mt1-mmp
-
chondrogenesis
-
medicine
-
stromelysin-1
-
diagnostics
-
cartilage-specific
-
condylar
-
analysis
-
osteophyte
-
drug development
-
aggrecanase
- 3.4.24.B4
- cartilage
- chondrocytes
- osteoarthritis
- metalloproteinases
- joint
-
articular
- aggrecan
- degeneration
- mmp-2
- tnf
- knee
- timp-1
- arthritis
- synovial
- interleukin-1
- proteoglycans
-
degener
- cox-2
- osteoblast
- adamts-5
- ligament
-
intra-articular
- collagenases
-
col2a1
- thrombospondin
- pulposus
- runx2
-
cruciate
-
zymography
-
chondrogenic
- gelatinase
- meniscus
-
intervertebral
-
subchondral
-
disintegrin
-
endochondral
-
safranin
- synoviocytes
-
collagenolytic
-
matrix-degrading
-
chondroprotective
-
ossification
-
temporomandibular
- mt1-mmp
-
chondrogenesis
- medicine
- stromelysin-1
- diagnostics
-
cartilage-specific
-
condylar
- analysis
- osteophyte
- drug development
- aggrecanase
Reaction
proteolytic degradation of proteins =
Synonyms
collagenase, collagenase 3, collagenase-3, M10.013, matrix metalloproteinase 13, matrix metalloproteinase-13, MMP-13, MMP13, MMP13a, More, UMRCASE
ECTree
Advanced search results
Application
Application on EC 3.4.24.B4 - matrix metalloproteinase-13
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
diagnostics
-
MMP-13 is a predictive markers for cisplatin resistance in head and neck squamous cell cancer
drug development
-
the enzyme is a target for design of tetracycline-based drugs
medicine
MMP-13 expression might be an indicator for increased extracellular matrix remodeling and early signs of vertebral compression in farmed Atlantic salmon
analysis
generation of a neutralizing antibody specifc for the active form of MMP-13, but not for the latent form, or other MMPs. antibody can be used to measure active MMP-13 selectively by an enzyme-linked immunosorbet assay. The antibody suppresses the cleavage of type II collagen in human articular chondrocyte cultures, and is thought to inhibit MMP-13 activity effectively
-
abundant expression of enzyme and of matrix metalloproteinase 10 in keratoacanthoma. Frequent expression of transformation-specific enzyme suggests that keratoacanthomas are incomplete squamous cell carcinomas
medicine
-
cartilaginous growth plate abnormalities result from enzyme deficiency in mice phenocopy defects observed in human hereditary chondrodysplasis
medicine
-
change of enzyme expression in response to caries attack. Extremely high enzyme mRNA expression in pooled pulp samples of sound and carious teeth, downregulation of enzyme expression during caries progression
medicine
-
during gastric ulcer healing, enzyme expression as well as matrix metalloproteinase MMP-2 and MMP-3 are induced in stromal cells of the gastric mucosa bordering the ulcer. Enzyme mRNA is confined to the upper layers of the granulation tissue
medicine
-
expression of enzyme and tissue inhibitor of matrix metalloproteinase, TIMP-1, is regulated by Wnt signaling combined with bone morphogenic protein BMP-2 in osteoblastic differentiation
medicine
-
high level of enzyme expression by fibroblasts achieved by adenoviral gene delivery results in potent enhancement of remodeling and contraction of 3D collagen
medicine
-
percentage of enzyme-positive cutaneous malignant melanomas correlates significantly and positively with the mitotic index in invasive cutaneous malignant melanoma. No significant association between tumoral enzyme expression and relapse-free survival in patients with invasive cutaneous malignant melanoma
medicine
-
selective inhibition of enzyme to inhibit cleavage of fibromodulin as a treatment for patients suffering from arthritis
medicine
-
selective inhibitors for enzyme for potential use in treatment of osteoarthritis
medicine
-
mRNA expressions of matrix metalloproteinase-13 is significantly enhanced in osteoarthritis subchondral bone osteoblasts compared to subchondral bone osteoblasts without osteoarthritis. The expressions of this gene is greater in patients with severe cartilage damage than in those with mild cartilage damage
medicine
-
orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Two series, quinazolinones and pyrido[3,4-d]pyrimidin-4-ones, that are potent and specific MMP-13 inhibitors, some of which are orally bioavailable. These specific MMP-13 inhibitors, occupying the unique S1'-specificity pocket, do not bind to the Zn2+ ion, effectively preventing cartilage damage in animal models of osteoarthritis without inducing musculoskeletal side effects when given at extremely high doses to rats
medicine
-
tumor-derived, but not stromal fibroblast-derived, MMP-13 correlates with aggressive tumor phenotypes, and inversely correlated with the overall survival of breast cancer patients. MMP-13 may serve as an independent prognostic factor for invasive breast cancer patients. MMP-13 may be particularly useful as a prognostic marker when evaluated along with Her-2/neu and lymph node status
medicine
-
MMP13 is a potential therapeutic target for breast cancer bone metastasis
medicine
in a collagen-induced arthritis model, MMP-12 and MMP-13 activity probes based on derived from substrates Y(NO2)GPLG-LEEAK(Abz)G-NH2 and Y(NO2)GPAG-LYEK(Abz)G-NH2, respectively, discriminate between the activities of the 2 enzymes. In the disease model, MMP13 activity probe activation increases gradually after disease onset and correlates with disease severity over a longer period of 15 days
medicine
patients with alcoholic liver cirrhosis (stage A, B, C) display increased blood serum levels of MMP13 and reduced concentrations of glutamic acid and glutamine compared to the control group. No significant differences are observed in the activity of MMP1 in alcoholics with or without liver cirrhosis or in controls